If its from supply to usage that likely entails the...

If its from supply to usage that likely entails the manufacturing of each device (the actual test) and either the assays themselves or partial revenue from each test conducted.

The numbers i did above break down the "manufacturer" as Hologic which is why i broke it down into gross revenue split and then the split from hologics profit as i am unsure where we actually fit in the revenue pie. The "seller share" listed above is the "manufacturer share". However i assumed that it would be what Hologic makes from each test given their quarterly revenue. Their net profit might be the $8 per test, but their gross revenue assuming 2.5Million tests are done annually would have to be the higher amount.

Mind you with the BINX STD stuff, Hologics Cytology section includes pap smears, cervical cancers and other womens health matters. Outside of this, they do have their own womens sexual health stuff, so it could be that there is a future arrangement built on that.